In two siblings with systemic lupus erythematosus (SLE), who experienced two episodes of psychosis each, a longitudinal study of autoantibodies, including antibodies to ribosomal P proteins, is described. In two of three evaluable periods of 15 weeks antedating psychosis a rise followed by a spontaneous drop in anti-P levels was recorded. In the third period antibodies to ribosomal protein P were absent. It is concluded that results with single samples are not informative, and that frequent measurement of antibodies to ribosomal protein P in patients with SLE may have limited predictive value for psychosis.
Neuropsychiatric manifestations occur in about half of all patients with systemic lupus erythematosus (SLE).1 Immunologically mediated vascular injury and the action of autoantibodies reactive with neurones are thought to play a part in their pathogenesis, but the cause and effect of these abnormalities are still not understood. 2 Recently, Bonfa et al described an association between psychosis in patients with SLE and the presence of autoantibodies to ribosomal P proteins,3 4and found that serum levels of these antibodies increase before the onsetofpyschosis. 4 We determined levels of autoantibodies, including antibodies to ribosomal protein P, in multiple serum samples from two carefully reported siblings with SLE who had two episodes ofpsychosis each. An increase, followed by a spontaneous fall in antiribosomal P protein levels was reported in two of three periods of 15 weeks antedating psychosis. In the third period autoantibodies to ribosomal P proteins were absent.
The data show that findings on anti-P in single samples are not informative and suggest that frequent measurement of antibodies to ribosomal protein P during the follow up of patients with SLE may have predictive value for psychosis.
Case reports CASE 1 An Indonesian woman, born in 1957, was diagnosed as having SLE in May 1982 when she had discoid skin lesions, butterfly rash, noninfectious fever, arthralgias, proteinuria (1) (2) (3) (4) (5) g/24 h), leucopenia (3 4x 109/l), and thrombocytopenia (platelets 69x109/l). Tests for antinuclear antibodies, autoantibodies to double stranded DNA (anti-dsDNA), and platelets were positive, and serum complement was low. This patient, a younger sister of case 1, born in 1960, was diagnosed as having chronic discoid lupus erythematosus at the age of 25. Both her parents and eight other siblings were healthy without signs of an autoimmune disease. Treatment with topical corticosteroids and antimalarial drugs was successful. In September 1987 she was admitted to another hospital because of malaise, myalgias, fever (39°C), and psychiatric abnormalities (bradyphrenia, blocking of thoughts, and paranoia). Oral ulceration and lymphadenopathy were found. Laboratory abnormalities included non-haemolytic anaemia (109 g/l), leucocytopenia (3 0x 109/1), raised creatine kinase and complement concentrations. Tests for antinuclear antibodies, anti-dsDNA, and antibodies to extractable nuclear antigens were negative. Systemic lupus erythematosus was diagnosed and treatment with 60 mg prednisone/day (1 2 mg/kg) was started the day after admission. After two days she left hospital against medical advice. Six days later she was seen at our outpatient department, still using 60 mg prednisone/day. The psychiatrist confirmed the presence of psychosis. There was diffuse loss of hair, proximal muscle weakness, (still) raised creatine kinase levels, and electromyographic findings compatible with myositis. Over the next month there was a complete recovery except for fatigue and alopecia. The daily dose of prednisone was gradually reduced.
In March 1988, while receiving 20 mg prednisone/day, there was recurrence of myositis, leucocvtopenia, a butterfly rash, and vasculitis on the palms of the hands. Prednisone was increased to 50 mg/day. Within 24 hours she became overtly psychotic, and was admitted to a psychiatric hospital after several attempts to commit suicide. Prednisone was continued and combined with haloperidol, promethazine chloride, and diazepam. At discharge, two months later, she was still depressed, anxious, and bradyphrenic. These symptoms gradually disappeared as the daily dose of prednisone was tapered. In October 1988, while receiving 22-5 mg prednisone/day, azathioprine (100 mg/day) was introduced and neuroleptic drugs stopped.
Materials and methods
From both patients serum samples were obtained during follow up and stored at -800C until use. Samples were tested without knowledge of the clinical data.
Antibodies to ribosomal phosphoproteins were determined by immunoblotting and measured by an enzyme linked immunosorbent assay (ELISA). We used an internal reference serum, which reacted in a similar fashion to a reference serum, in both the immunoblotting assays and ELISAs.
In the immunoblotting assay5 a rat liver ribosomal extract, essentially prepared as described by Fairhurst, 6 Serum samples were screened for anti-dsDNA by indirect immunofluorescence on Crithidia luciliae9; positive sera were tested in a modified Farr assay. 10 Values above 10 U/ml (using 50 ,ul serum corresponding with more than 15% binding of 100 ng 3H labelled circular bacteriophage (PM2) DNA) are positive. Selected sera were tested in the polyethylene glycol assay. 9 Antibodies to cardiolipin (ACA) and tetanus toxoid were determined with ELISA techniques. 1 12 Concentrations of the complement components C3 and C4 were measured by laser nephelometry (Hyland, Costa Mesa, California) and of Clq by radial immunodiffusion.
Results
In patient 1 the anti-P value increased from 12 U (two weeks after spienectomy) to 23 U over a period of seven months. Simultaneously, antidsDNA increased from 11 to 470 U/ml . Five weeks later, at the time of psychosis, antibodies to P proteins were absent, and anti-dsDNA 1100 U/ml. Since then, antibodies to P proteins have remained undetectable for at least four years. This period included a second exacerbation with psychosis (unrelated to infection, metabolic disturbances, or drugs), which was again preceded by a rise in anti-dsDNA from negative (week 197) to 644 U/ml (week 244). Except for samples drawn between weeks 197 and 244, which were low positive (<80 U) for ACA-IgG, all samples were negative for both ACA-IgG and ACA-IgM. The 3) . A similar pattern has been described previously for anti-dsDNA levels during exacerbations of lupus nephritis.'4 It is tempting to interpret this pattern as an indication for complexation of antibodies to specific antigens and thus suggestive of a pathogenetic role for autoantibodies. The apparent autonomy of anti-P formation, which is manifested by the independence of anti-P levels from the level of other autoantibodies (anti-dsDNA, ACA) or polyclonal activation (antibodies to tetanus toxoid), supports this suggestion. The absence of anti-P before, during, and after the second episode of psychosis in case 1, however, argues against a causal relation between antibodies to P proteins and psychosis, and reduces the significance of the anti-P assay as a prognostic tool. The latter the more so as both episodes of psychosis in case 1 were clinically identical and no other cause than lupus could be found.
In conclusion, our data indicate that the levels of antibodies to P proteins in single samples are not informative and that frequent measurement of anti-P levels in order to find an increase followed by a spontaneous fall may have predictive value for psychosis in patients with SLE. Clearly, more patients should be evaluated to determine whether the discordancy between anti-P and psychosis we noted in one out of three prepsychotic periods forms a rare exception or a regularly occurring phenomenon. recurrent psychosis.
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